Proton-pump inhibitor use is associated with low serum magnesium concentrations

Kidney International

Volumn 83, Issue 4, 2013, Pages 692-699

  Danziger, John ^a   William, Jeffrey H ^a   Scott, Daniel J ^b   Lee, Joon ^b   Lehman, Li Wei ^b   Mark, Roger G ^b   Howell, Michael D ^a   Celi, Leo A ^a,b   Mukamal, Kenneth J ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

diuretics; electrolytes; gastrointestinal medications; mineral metabolism

Indexed keywords

DIURETIC AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; LOOP DIURETIC AGENT; MAGNESIUM; PROTON PUMP INHIBITOR; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; HYPOMAGNESEMIA; INTENSIVE CARE UNIT; KIDNEY DISEASE; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STOMACH ACID; TERTIARY HEALTH CARE;

EID: 84875728378     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.452     Document Type: Article

References (47)

1. IMS Health INSP, Top Therapy Classes by United States Dispensed Presciptions, Data from 2007. Accessed March 2011. Available at: http://www.imshealth.com/portal/site/ims.
2. Herzig SJ, Howell MD, Ngo LH et al. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009; 301: 2120-2128.
3. Ray S, Delaney M, Muller AF. Proton pump inhibitors and acute interstitial nephritis. BMJ 2010; 341: c4412.
4. Sierra F, Suarez M, Rey M et al. Systematic review: proton pump inhibitorassociated acute interstitial nephritis. Aliment Pharmacol Ther 2007; 26: 545-553.
5. Cunningham R, Dale B, Undy B et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003; 54: 243-245.
6. Howell MD, Novack V, Grgurich P et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170: 784-790.
7. Faulhaber GA, Furlanetto TW. Could magnesium depletion play a role on fracture risk in PPI users? Arch Intern Med 2010; 170: 1776.
8. Abraham NS, Hlatky MA, Antman EM et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 2010; 56: 2051-2066.
9. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006; 355: 1834-1836.
10. Metz DC, Sostek MB, Ruszniewski P et al. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol 2007; 102: 2648-2654.
11. Shabajee N, Lamb EJ, Sturgess I et al. Omeprazole and refractory hypomagnesaemia. BMJ 2008; 337: a425.
12. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf) 2008; 69: 338-341.
13. Broeren MA, Geerdink EA, Vader HL et al. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med 2009; 151: 755-756.
14. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors-a review. Neth J Med 2009; 67: 169-172.
15. Hoorn EJ, van der Hoek J, de Man RA et al. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010; 56: 112-116.
16. Regolisti G, Cabassi A, Parenti E et al. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis 2010; 56: 168-174.
17. Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM 2010; 103: 387-395.
18. Cundy T, Mackay J. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol 2011; 27: 180-185.
19. Quasdorff M, Mertens J, Dinter J et al. Recurrent hypomagnesemia with proton-pump inhibitor rechallenge. Ann Intern Med 2011; 155: 405-407.
20. Furlanetto TW, Faulhaber GA. Hypomagnesemia and proton pump inhibitors: below the tip of the iceberg. Arch Intern Med 2011; 171: 1391-1392.
21. US Department of Health and Human Services F, Drug Safety Communication. Proton Pump Inhibitor drugs (PPIs): Drug Safety Communication-Low Magnesium Levels Can Be Associated With Long-Term Use. (updated 03 March 2011; cited); Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm245275.htm.
22. Flink EB. Magnesium deficiency. Etiology and clinical spectrum. Acta Med Scand Suppl 1981; 647: 125-137.
23. Vallee BL, Wacker WE, Ulmer DD. The magnesium-deficiency tetany syndrome in man. N Engl J Med 1960; 262: 155-161.
24. Moore MJ, Flink EB. Magnesium deficiency as a cause of serious arrhythmias. Arch Intern Med 1978; 138: 825-826.
25. Reffelmann T, Ittermann T, Dorr M et al. Low serum magnesium concentrations predict cardiovascular and all-cause mortality. Atherosclerosis 2011; 219: 280-284.
26. Reffelmann T, Dorr M, Ittermann T et al. Low serum magnesium concentrations predict increase in left ventricular mass over 5 years independently of common cardiovascular risk factors. Atherosclerosis 2010; 213: 563-569.
27. Sapna S, Ranjith SK, Shivakumar K. Cardiac fibrogenesis in magnesium deficiency: a role for circulating angiotensin II and aldosterone. Am J Physiol Heart Circ Physiol 2006; 291: H436-H440.
28. Sontia B, Touyz RM. Magnesium transport in hypertension. Pathophysiology 2007; 14: 205-211.
29. Sontia B, Touyz RM. Role of magnesium in hypertension. Arch Biochem Biophys 2007; 458: 33-39.
30. Barbagallo M, Dominguez LJ, Galioto A et al. Oral magnesium supplementation improves vascular function in elderly diabetic patients. Magnes Res 2010; 23: 131-137.
31. Barbagallo M, Dominguez LJ. Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. Arch Biochem Biophys 2007; 458: 40-47.
32. Gau JT, Yang YX, Chen R et al. Uses of proton pump inhibitors and hypomagnesemia. Pharmacoepidemiol Drug Saf 2012; 21: 553-559.
33. Schlingmann KP, Weber S, Peters M et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 2002; 31: 166-170.
34. Hou J, Renigunta A, Konrad M et al. Claudin-16 and claudin-19 interact and form a cation-selective tight junction complex. J Clin Invest 2008; 118: 619-628.
35. Quamme GA. Control of magnesium transport in the thick ascending limb. Am J Physiol 1989; 256(Part 2): F197-F210.
36. Dai LJ, Ritchie G, Kerstan D et al. Magnesium transport in the renal distal convoluted tubule. Physiol Rev 2001; 81: 51-84.
37. Thongon N, Krishnamra N. Omeprazole decreases magnesium transport across Caco-2 monolayers. World J Gastroenterol 2011; 17: 1574-1583.
38. Wallach S. Effects of magnesium on skeletal metabolism. Magnes Trace Elem 1990; 9: 1-14.
39. Yang YX, Lewis JD, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-2953.
40. Targownik LE, Lix LM, Metge CJ et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008; 179: 319-326.
41. Targownik LE, Lix LM, Leung S et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138: 896-904.
42. Targownik LE, Leslie WD. The relationship among proton pump inhibitors, bone disease and fracture. Expert Opin Drug Saf 2011; 10: 901-912.
43. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
44. Saeed M, Villarroel M, Reisner AT et al. Multiparameter Intelligent Monitoring in Intensive Care II: a public-access intensive care unit database. Crit Care Med 2011; 39: 952-960.
45. Curiel-Garcia JA, Rodriguez-Moran M, Guerrero-Romero F. Hypomagnesemia and mortality in patients with type 2 diabetes. Magnes Res 2008; 21: 163-166.
46. Pham PC, Pham PM, Pham SV et al. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007; 2: 366-373.
47. Elixhauser A, Steiner C, Harris DR et al. Comorbidity measures for use with administrative data. Med Care 1998; 36: 8-27.